Kerri Fitzgerald

DocwireNews

<p>The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/cd19-car-t-b-cell/">chimeric antigen receptor</a> (CAR) T-cell therapy CT053, a fully human anti-B-cell maturation antigen autologous CAR T-cell therapy, for the treatment of relapsed/refractory multiple myeloma (MM).<h2>Responses observed with CT053</h2><p>The decision for RMAT designation was based on data from an ongoing phase I study in heavily pretreated patients with MM in China. So far, 19 of 24 patients with relapsed/refractory MM had a complete response to therapy, with no cases of grade 3/4 <a href="https://www.docwirenews.com/abstracts/hem-onc-abstracts/t-cell-receptor-stimulation-cd19/">cytokine release syndrome</a> observed during the study. Further data from this trial will be presented at the upcoming American Society of Hematology 2019 Annual Meeting.</p><p>RMAT designation is a program designed to expedite the drug development and review processes for promising regenerative medicines and advanced therapies, including CAR T-cell therapies. The designation is similar to that of fast track and breakthrough therapy designations, providing the ability for early interactions with FDA senior management to discuss surrogate or intermediate endpoints, potential ways to support accelerated approval and satisfy post-approval requirements, potential priority review of the biologics license application, and other opportunities to expedite development and review.</p><p>To date, 44 agents have received RMAT designation.</p></p>


Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

FDA Grants RMAT Designation for CAR T-Cell Therapy for Multiple Myeloma

Oncology

The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to the investigational chimeric antigen receptor (CAR) T-cell ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe